More affordable human vaccines on cards

Our Bureau

Cheaper remedy


IIL is

expected to price its Hepatitis-B vaccine at around 40 per cent lower than other Hepatitis-B vaccines currently in the market

This is

expected to make it more affordable and also ensure its wider availability

Hyderabad, Sept. 24

Giving both the Indian private sector players and multinationals into production and marketing of Hepatitis-B vaccine a run for their money, the public sector player National Dairy Development Board (NDDB) has launched its low-cost recombinant DNA Hepatitis-B vaccine under the brand Elovac-B.

The vaccine is indigenously manufactured by Human Biologicals Institution (HBI) at its facility located at Gachibowli here. HBI is a division of Indian Immunologicals Ltd (IIL), which is a wholly owned subsidiary of NDDB.

More vaccines

Addressing newspersons on the eve of launching the product here, the IIL Managing Director, Mr K.V. Balasubramaniam, said the institute would also be coming out soon with more human vaccines such as measles, DPT, TT and combination vaccines. While vaccine for measles would be launched before the year-end, the DPT vaccine would hit the market before the fiscal-end. The combination vaccine is expected to be in the market during the next fiscal, he said.

Cheaper price

Mr Balasubramaniam said IIL would be pricing its Hepatitis-B vaccine around 40 per cent lower than the products of the Indian private sector manufacturers and MNCs currently in the market.

IIL would be making its products available through the vast network of over 2,000 Abhay Clinics across the country, apart from institutional channels.

"This idea is not only to help ensure availability of Hepatitis-B vaccine to the large population across the country at highly affordable prices but also to ensure greater availability of the vaccine," he said.

Elovac-B

Further, he said Elovac-B would significantly gain from the Government's proposal to include Hepatitis-B vaccine in the Extended Programme of Immunisation (EPI), which is expected shortly.

IIL has a manufacturing capacity of 200-million doses of Elovac-B at the facility set up around Rs 50 crore.

He said that Elovac-B offers purity exceeding specifications provided by the regulatory authorities, and hence ensures best protection.

(This article was published in the Business Line print edition dated September 25, 2006)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.